PDCD1 and cancer: Cancer immunotherapy based on blockade of the programmed cell death protein 1 (PD-1)/PD-1 ligand 1 (PD-L1) pathway with monoclonal antibodies is increasingly applied in clinical practice [1,2,3,4].